DE60134234D1 - Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese - Google Patents

Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese

Info

Publication number
DE60134234D1
DE60134234D1 DE60134234T DE60134234T DE60134234D1 DE 60134234 D1 DE60134234 D1 DE 60134234D1 DE 60134234 T DE60134234 T DE 60134234T DE 60134234 T DE60134234 T DE 60134234T DE 60134234 D1 DE60134234 D1 DE 60134234D1
Authority
DE
Germany
Prior art keywords
nucleic acid
pharmaceutical compositions
acid constructs
vascular cells
inducing angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134234T
Other languages
German (de)
English (en)
Inventor
Moshe Y Flugelman
Zoya Gluzman
Meir Preis
Belly Koren
Tzafra Cohen
Adili Tsaba
Anat Weisz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multi Gene Vascular Systems Ltd MGVS
Original Assignee
Multi Gene Vascular Systems Ltd MGVS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multi Gene Vascular Systems Ltd MGVS filed Critical Multi Gene Vascular Systems Ltd MGVS
Application granted granted Critical
Publication of DE60134234D1 publication Critical patent/DE60134234D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60134234T 2000-08-08 2001-08-08 Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese Expired - Lifetime DE60134234D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22372700P 2000-08-08 2000-08-08
PCT/IL2001/000733 WO2002012539A2 (en) 2000-08-08 2001-08-08 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis

Publications (1)

Publication Number Publication Date
DE60134234D1 true DE60134234D1 (de) 2008-07-10

Family

ID=22837748

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134234T Expired - Lifetime DE60134234D1 (de) 2000-08-08 2001-08-08 Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese

Country Status (13)

Country Link
US (1) US7767201B2 (enExample)
EP (2) EP2163642A1 (enExample)
JP (1) JP2004520009A (enExample)
AT (1) ATE397087T1 (enExample)
AU (1) AU2001280060A1 (enExample)
CA (1) CA2418936A1 (enExample)
CZ (1) CZ2003444A3 (enExample)
DE (1) DE60134234D1 (enExample)
HU (1) HUP0300727A3 (enExample)
IL (1) IL154324A0 (enExample)
PL (1) PL366000A1 (enExample)
WO (1) WO2002012539A2 (enExample)
ZA (1) ZA200301386B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387645B2 (en) * 2003-04-25 2008-06-17 Medtronic Vascular, Inc. Cellular therapy to heal vascular tissue
WO2006130320A2 (en) * 2005-05-11 2006-12-07 University Of Florida Research Foundation, Inc. Repair of the bone marrow vasculature
WO2007059303A2 (en) * 2005-11-15 2007-05-24 The Board Of Trustees Of The Leland Stanford Junior University Compositions for coordinated vegf and pdgf expression, and methods of use
JP5121155B2 (ja) * 2006-03-14 2013-01-16 独立行政法人物質・材料研究機構 形質転換細胞集団の作成方法
WO2007136673A2 (en) * 2006-05-19 2007-11-29 Medistem Laboratories, Inc. Treatment of disc degenerative disease and compositions for same
WO2008152507A2 (en) * 2007-03-16 2008-12-18 Multigene Vascular Systems, Inc. Compositions and methods for treating ophthalmic disorders
CN102242148A (zh) * 2010-10-09 2011-11-16 苏州大学 重组载体以及转基因骨髓基质细胞修饰的丝素膜及其应用
US10383916B2 (en) 2012-11-02 2019-08-20 Cornell University Angiogenic conditioning to enhance cardiac cellular reprogramming of fibroblasts of the infarcted myocardium
CN114457003A (zh) * 2020-11-10 2022-05-10 维思尔治疗有限公司 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900556A (en) * 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6001350A (en) 1987-12-11 1999-12-14 Somatix Therapy Corp Genetic modification of endothelial cells
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
EP0642585B1 (en) * 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US5618544A (en) * 1992-08-12 1997-04-08 Bays-Brown Dermatologics, Inc. Method of decreasing cutaneous senescence
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US6007987A (en) 1993-08-23 1999-12-28 The Trustees Of Boston University Positional sequencing by hybridization
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5821919A (en) * 1994-04-29 1998-10-13 Intel Corporation Apparatus for table-driven conversion of pixels from YVU to RGB format
US6090618A (en) * 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5941868A (en) 1995-12-22 1999-08-24 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5785965A (en) * 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
CN1244772A (zh) * 1996-10-23 2000-02-16 威克福雷大学 靶向性细胞毒性细胞
FI970784L (fi) * 1997-02-25 1998-08-26 Nokia Telecommunications Oy Prosessien välinen vuonvalvonta hajautetussa moniprosessoriympäristössä
US6099832A (en) * 1997-05-28 2000-08-08 Genzyme Corporation Transplants for myocardial scars
CA2225185A1 (en) * 1997-08-11 1999-02-11 Peter K. Law Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
CA2266805C (en) * 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US6206914B1 (en) * 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
PL199645B1 (pl) * 1998-12-23 2008-10-31 Regeneron Pharma Kwas nukleinowy, polipeptyd fuzyjny, kompozycja, wektor, wektor ekspresyjny, układ gospodarz wektor, sposób wytwarzania polipeptydu fuzyjnego, kwas nukleinowy i sposób wytwarzania polipeptydu fuzyjnego
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6328762B1 (en) * 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
US6554857B1 (en) * 1999-07-20 2003-04-29 Medtronic, Inc Transmural concentric multilayer ingrowth matrix within well-defined porosity
US6753321B2 (en) 2000-09-15 2004-06-22 Genvec, Inc. Method of modulating neovascularization
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins

Also Published As

Publication number Publication date
ZA200301386B (en) 2004-03-31
IL154324A0 (en) 2003-09-17
US7767201B2 (en) 2010-08-03
US20040151707A1 (en) 2004-08-05
WO2002012539A3 (en) 2002-05-16
EP2163642A1 (en) 2010-03-17
HUP0300727A2 (hu) 2003-10-28
EP1307582A4 (en) 2004-09-22
EP1307582B1 (en) 2008-05-28
CA2418936A1 (en) 2002-02-14
ATE397087T1 (de) 2008-06-15
HUP0300727A3 (en) 2005-12-28
JP2004520009A (ja) 2004-07-08
CZ2003444A3 (cs) 2003-10-15
WO2002012539A2 (en) 2002-02-14
EP1307582A2 (en) 2003-05-07
AU2001280060A1 (en) 2002-02-18
PL366000A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1226109A4 (en) PHENYLAMINE CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DISPENSING ACTIVE AGENTS
DE60126923D1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
ATE369894T1 (de) Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DK1487416T3 (da) Lægemiddelmikropartikler
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ATE530197T1 (de) Medizinische zusammensetzungen zur angiogenese- therapie
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
PT1358177E (pt) Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica
NO20073914L (no) Biologisk aktive peptider
DE60134234D1 (de) Nukleinsäurekonstrukte, damit transformierte vaskuläre zellen, pharmezeutische zusammensetzungen und verfahren zur induktion der angiogenese
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
FR2833956B1 (fr) Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
ATE489466T1 (de) Nukleinsäuren zur hemmung der expression von hairless-protein und verfahren zur verwendung davon
FR2827287B1 (fr) Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60200041D1 (de) Indenoindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
BR0112123A (pt) Composto
MA27088A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compostions pharmaceutiques qui les contiennent
WO2003040119A8 (fr) Inhibiteurs de l'angiogenese
DE60222288D1 (de) Verfahren zur herstellung von hohlkörpern, vorformlinge dafür und nach diesem verfahren hergstellte flaschen
FR2827280B1 (fr) Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition